The tweet was deleted by the author.
But we saved everything 🙂.
Immuneering CEO Ben Zeskind presented the company unique approach to developing therapies aimed at improving outcomes for cancer patients during a recent conversation on the BrewMarkets podcast.
The discussion with Ann Berry focused on initial progress and research in areas such as pancreatic cancer, positioning Immuneering as an innovator targeting significant unmet needs in oncology. Zeskind detailed steps the company is taking to create impactful therapeutic solutions, with an emphasis on scientific differentiation and patient-focused results.
Immuneering recently introduced its Deep Cyclic Inhibitor strategy aimed at lowering cancer therapy toxicity to help preserve patient quality of life, according to a company announcement. The firm has also provided updates on progress in meetings with potential partners, including at BioEurope Spring, where Chief Business Officer E B Brakewood discussed development milestones in one-on-one sessions last spring. These efforts align with the company’s ongoing focus on advancing oncology research and partnerships.